Selective estrogen receptor modulators: Women's panacea for the next millennium? (Q33540949)

27 July 2017

1 reference

title

Selective estrogen receptor modulators: Women's panacea for the next millennium? (English)

1 reference

27 July 2017

C P Spencer

1

1 reference

27 July 2017

E P Morris

series ordinal

2

1 reference

27 July 2017

J M Rymer

series ordinal

3

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

American Journal of Obstetrics and Gynecology

27 July 2017

1 reference

27 July 2017

180

1 reference

27 July 2017

3 Pt 1

1 reference

27 July 2017

763-770

1 reference

Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel.

27 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The Framingham Disability Study: relationship of various coronary heart disease manifestations to disability in older persons living in the community

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Breast cancer trends. Incidence, mortality, and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Changing incidence and residual lifetime risk of common osteoporosis-related fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Perspective. How many women have osteoporosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Long-term estrogen replacement therapy prevents bone loss and fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Hormone therapy to prevent disease and prolong life in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Postmenopausal hormone therapy and mortality.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

A new derivative of triphenylethylene: effect on implantation and mode of action in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Role of Estrogens in Ovulation: A Study Using the Estrogen-Antagonist, I.C.I. 46,474

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effect of some triphenylethylenes on oestradiol binding in vitro to macromolecules from uterus and anterior pituitary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Tamoxifen as an anti-tumour agent: oestrogen binding as a predictive test for tumour response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effects of tamoxifen on spinal bone density in women with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Oestrogen and bone density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Apparent beneficial effects of tamoxifen on bone mineral content in patients with breast cancer: Preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effect of long term tamoxifen treatment on bone turnover in women with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Bone mineral content of women receiving tamoxifen for mastalgia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Antiestrogen and antiandrogen administration reduce bone mass in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Does long-term administration of tamoxifen affect bone mineral density?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Risk of endometrial cancer after tamoxifen treatment of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

What do we know and what don't we know about tamoxifen in the human uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Pathology of endometrium treated with tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

7 January 2021

Tamoxifen and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Mechanisms of action of antiestrogens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Cloning of a novel receptor expressed in rat prostate and ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Antagonism of estrogen action with a new benzothiophene derived antiestrogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The effects of raloxifene on tibia histomorphometry in ovariectomized rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Raloxifene preserves bone strength and bone mass in ovariectomized rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Preclinical data for Droloxifene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Pharmacologic and biologic properties of droloxifene, a new antiestrogen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Pharmacokinetics of droloxifene and its metabolites in breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Droloxifene, a new antiestrogen: its role in metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy X-ray absorptiometric and histomorphometric study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Common mechanism for the estrogen agonist and antagonist activities of droloxifene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Induction of Transforming Growth Factor β by the Antiestrogens Droloxifene, Tamoxifen, and Toremifene in MCF-7 Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Centchroman: a new non-steroidal oral contraceptive in human milk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The bone-specific estrogen centchroman inhibits osteoclastic bone resorption in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Centchroman--a non-steroidal anti-cancer agent for advanced breast cancer: phase-II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Antitumor effect of triphenylethylene derivative (TAT-59) against human breast carcinoma xenografts in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

17 beta-estradiol increases calcium content in fetal mouse parietal bones cultured in serum-free medium only at physiological concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

Action of "pure" antiestrogens in inhibiting estrogen receptor action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

The effect of anti-oestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2899%2970285-1

10.1016/S0002-9378(99)70285-1

7 January 2021

Identifiers

DOI

1 reference

27 July 2017

1 reference